Discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and topical diseases that stem from dysbiosis.
HepaRx is a biopharmaceutical company aiming to develop a proprietary small molecule (SMC) cancer drug
Ice Therapeutics is a preclinical-stage biopharmaceutical company engaged in developing proprietary small molecules for treating neuropathic pain associated with cold intolerance.
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy.
MabTrix is a preclinical stage biopharmaceutical company aiming to develop an innovative, function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) as the initial indication
Mitoconix Bio Ltd is pioneering a novel strategy to improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug.
Protekt Therapeutics is a biopharmaceutical company aiming to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI)
XL Therapeutics is a biopharmaceutical company aiming to develop small molecule compounds (SMCs) to treat patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT)
XoNovo is a biopharmaceutical company developing proprietary small molecules for the treatment of neurodegenerative diseases